If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02738931","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Treatment Sequence ABC","arm_group_description":"Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"},{"arm_group_label":"Treatment Sequence BCA","arm_group_description":"Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"},{"arm_group_label":"Treatment Sequence CAB","arm_group_description":"Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"},{"arm_group_label":"Treatment Sequence ACB","arm_group_description":"Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"},{"arm_group_label":"Treatment Sequence BAC","arm_group_description":"Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"},{"arm_group_label":"Treatment Sequence CBA","arm_group_description":"Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Fixed dose combination (FDC) tablets of existing approved drugs are preferred by many patients and offer the potential for increased patient adherence and consequently a reduced likelihood of virological failure and viral resistance. The purpose of the present study is to evaluate the relative bioavailability of two experimental FDC tablets of DTG and 3TC relative to co-administration of the single entity products in healthy adult subjects. This study will be conducted as a randomized, open label three-way, crossover design with 6 treatment sequences in approximately 30 subjects. Each subject will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods each with a single dose of study drug and a follow-up visit within 7-14 days after the last dose of study drug. There will be at least 7 days washout between dosing periods. The total duration of participation of a subject in this study will be approximately 9 weeks.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Relative bio-availability study of dolutegravir and lamivudine fixed dose combinations","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:42:26","criteria":"Inclusion Criteria - Between 18 and 65 years of age inclusive, at the time of signing the informed consent. - Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation (history, electrocardiogram [ECG]). - A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. - Body weight >= 50 kilogram (kg) (110 pounds [lbs.)] for men and >= 45 kg (99 lbs) for women and body mass index (BMI) within the range 18.5-31.0 kg/meter square (m^2) (inclusive) - Male or Female Female subject of non-reproductive potential: is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: • Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy • Postmenopausal defined as 12 months of spontaneous amenorrhea; in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in protocol. Exclusion Criteria - Alanine transaminase (ALT) and bilirubin >1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). - Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). - QT interval corrected for heart rate according to Fridericia’s formula (QTcF) > 450 millisecond (msec) - Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and ViiV/GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. - History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits. - Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 1 month prior to screening. - History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. - Creatinine clearance (CrCL) <60 mL/minute (min) - A positive hepatitis B surface antigen (HBsAg) or a or a positive hepatitis B core antibody with a negative hepatitis B surface antibody, positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. - A positive pre-study drug/alcohol screen. - A positive test for human immunodeficiency virus (HIV) antibody. - Where participation in the study would result in donation of blood or blood product in excess of 500 mL within 56 days. - The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). - Exposure to more than four new chemical entities within 12 months prior to the first dosing day.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"30","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"4b6593a8-5222-5f55-9fda-fe2a040f0f2d","internal":{"content":null,"contentDigest":"7aad7a5967741439ce8aa06119b88da9","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria - Between 18 and 65 years of age inclusive, at the time of signing the informed consent. - Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation (history, electrocardiogram [ECG]). - A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. - Body weight >= 50 kilogram (kg) (110 pounds [lbs.)] for men and >= 45 kg (99 lbs) for women and body mass index (BMI) within the range 18.5-31.0 kg/meter square (m^2) (inclusive) - Male or Female Female subject of non-reproductive potential: is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: • Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy • Postmenopausal defined as 12 months of spontaneous amenorrhea; in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in protocol. Exclusion Criteria - Alanine transaminase (ALT) and bilirubin >1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). - Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). - QT interval corrected for heart rate according to Fridericia’s formula (QTcF) > 450 millisecond (msec) - Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and ViiV/GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. - History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits. - Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 1 month prior to screening. - History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. - Creatinine clearance (CrCL) <60 mL/minute (min) - A positive hepatitis B surface antigen (HBsAg) or a or a positive hepatitis B core antibody with a negative hepatitis B surface antibody, positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. - A positive pre-study drug/alcohol screen. - A positive test for human immunodeficiency virus (HIV) antibody. - Where participation in the study would result in donation of blood or blood product in excess of 500 mL within 56 days. - The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). - Exposure to more than four new chemical entities within 12 months prior to the first dosing day.","interventions":[{"arm_group_label":"Treatment Sequence BCA","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ABC","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CAB","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CBA","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BAC","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ACB","intervention_description":"A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir 50 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BCA","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ABC","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CAB","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CBA","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BAC","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ACB","intervention_description":"Gray, diamond-shaped tablet, engraved “GX EJ7” on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Lamivudine 300 mg tablet","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BCA","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ABC","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CAB","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CBA","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BAC","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ACB","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BCA","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ABC","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CAB","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence CBA","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence BAC","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"},{"arm_group_label":"Treatment Sequence ACB","intervention_description":"Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.","intervention_name":"Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["dolutegravir","lamivudine","Bioavailability","fixed dose combinations"],"last_follow_up_date":"06/01/2016 00:00:00","links":[],"locations":[{"City":"Overland Park","Latitude":"38.9221969","CountryDisplay":"United States","Longitude":"-94.6295394","Name":"GSK Investigational Site","StateDisplay":"Kansas","PostalCode":"66211","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"65 years","maximum_age":"65","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:39:32","number_of_arms":"6","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects","org_study_id":"204993","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"06/01/2016 00:00:00","primary_outcomes":[{"outcome_description":"Serial blood samples for pharmacokinetic (PK) analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC[0-inf])","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: maximum concentration observed (Cmax)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: AUC(0-inf)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: Cmax","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Area under the concentration-time curve from time 0 to the last measurable timepoint (AUC[0-t])","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Drug concentration at 24 hours post-dose (C24)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Half-life (t1/2)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Absorption lag time (tlag)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Time to observed maximal drug concentration (tmax)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of DTG will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"DTG: Apparent oral clearance (CL/F)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC:AUC(0-t)","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: C24","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC:t1/2","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: tlag","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: tmax","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"Serial blood samples for PK analysis of 3TC will be collected. From the plasma concentration-time data, the PK parameters will be determined.","outcome_measure":"3TC: CL/F","outcome_time_frame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 9, 12, 16, 24, and 48 hours post-dose","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in temperature","outcome_time_frame":"Baseline and up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in systolic and diastolic blood pressure (BP)","outcome_time_frame":"Baseline and up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in pulse rate","outcome_time_frame":"Baseline and up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with adverse events","outcome_time_frame":"Up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"The hematology parameters included are platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), neutrophils, lymphocytes, monocytes, eosinophils, basophils.","outcome_measure":"Number of subjects with the Toxicity Grade and Change from baseline summary for the Indicated Hematology Parameters","outcome_time_frame":"Up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"Clinical chemistry parameters included are blood urea nitrogen (BUN), creatinine, glucose, creatine phosphokinase (CPK), potassium, sodium, calcium, AST, ALT, alkaline phosphatase, total and direct bilirubin, total protein, albumin","outcome_measure":"Number of subjects with the Toxicity Grade and Change from baseline summary for the Indicated Clinical Chemistry Parameters","outcome_time_frame":"Up to 9 weeks","outcome_safety_issue":null},{"outcome_description":"Urinalysis parameters included are specific gravity, pH, glucose, protein, blood and ketones by dipstick, microscopic examination (if blood or protein is abnormal)","outcome_measure":"Number of subjects with urinalysis abnormalities","outcome_time_frame":"Up to 9 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"05/01/2016 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"204993"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}